![](http://img1.wsimg.com/isteam/ip/52c4f651-6804-4f11-a210-d41e33f401de/ZUNVEYL%20hdr_0002_Gradient%20Sun-bfcbfff.jpg/:/)
ZUNVEYL® is Now FDA-Approved
In Q1 of 2025, ZUNVEYL will be commercially available. Click here if you'd like to receive more information.
In Q1 of 2025, ZUNVEYL will be commercially available. Click here if you'd like to receive more information.
ZUNVEYL is a prescription cholinesterase inhibitor
indicated for the treatment
of mild to moderate dementia
of the Alzheimer’s type
in adults.
Sign up here to receive news on ZUNVEYL, including updates on release dates, product updates and more.
ZUNVEYL® (benzgalantamine) is a cholinesterase inhibitor indicated for the treatment of mild to moderate dementia of the Alzheimer’s type in adults.
ZUNVEYL is contraindicated in patients with known hypersensitivity to benzgalantamine, galantamine, or any inactive ingredients in ZUNVEYL.
The most common adverse reactions with galantamine tablets (≥5%) were nausea, vomiting, diarrhea, dizziness, headache, and decreased appetite.
Cholinesterase inhibitors, including galantamine, have the potential to interfere with the activity of anticholinergic medications. A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents, or cholinergic agonists such as bethanechol.
These are not all of the possible side effects of ZUNVEYL. You can report side effects to the FDA. Visit www.fda.gov/MedWatch or call 1‑800‑FDA‑1088. Please click the Full Prescribing Information tab above.
Copyright © 2024 ZUNVEYL - All Rights Reserved.
Powered by GoDaddy
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.